Blueprint Medicines (LTS:0HOJ) Debt-to-Equity : 1.06 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Blueprint Medicines Debt-to-Equity?

Blueprint Medicines's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $42.4 Mil. Blueprint Medicines's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $287.7 Mil. Blueprint Medicines's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $310.7 Mil. Blueprint Medicines's debt to equity for the quarter that ended in Mar. 2024 was 1.06.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Blueprint Medicines's Debt-to-Equity or its related term are showing as below:

LTS:0HOJ' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.08 Max: 2.55
Current: 1.06

During the past 11 years, the highest Debt-to-Equity Ratio of Blueprint Medicines was 2.55. The lowest was 0.02. And the median was 0.08.

LTS:0HOJ's Debt-to-Equity is ranked worse than
87.69% of 1072 companies
in the Biotechnology industry
Industry Median: 0.14 vs LTS:0HOJ: 1.06

Blueprint Medicines Debt-to-Equity Historical Data

The historical data trend for Blueprint Medicines's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blueprint Medicines Debt-to-Equity Chart

Blueprint Medicines Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.21

0.06

0.12

0.47

2.55

Blueprint Medicines Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.58	0.77	1.65	2.55	1.06

Competitive Comparison of Blueprint Medicines's Debt-to-Equity

For the Biotechnology subindustry, Blueprint Medicines's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Blueprint Medicines's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Blueprint Medicines's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Blueprint Medicines's Debt-to-Equity falls into.

Blueprint Medicines Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Blueprint Medicines's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(42.211	+	290.286)	/	130.609
	=	2.55

Blueprint Medicines's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(42.42	+	287.694)	/	310.687
	=	1.06

Blueprint Medicines (LTS:0HOJ) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Blueprint Medicines Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Blueprint Medicines's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Blueprint Medicines (LTS:0HOJ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Blueprint Medicines Corp (LTS:0HOJ) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

BPMC:USA 2L9:Germany

Address

45 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.blueprintmedicines.com

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.

Blueprint Medicines (LTS:0HOJ) Headlines

No Headlines